Aims and Scope of Therapeutic Innovation and Regulatory Science
Therapeutic Innovation & Regulatory Science is a bimonthly peer-reviewed medical journal that covers research and developments concerning pharmaceuticals and the development and use of medical products. It is published by Sage Publications on behalf of the Drug Information Association. The journal was established in 1967 as the Drug Information Bulletin and renamed to Drug Information Journal in 1971, before obtaining its current title in 2013. The editor-in-chief is Stephen P. Spielberg. Less
Key Metrics
CiteScore 

2.2
H-Index 

48
Impact Factor 

< 5
SJR 

Q2Pharmacology (medical)

SNIP 

0.6
Recommended pre-submission checks
Powered by 

Topics Covered on Therapeutic Innovation and Regulatory Science
Therapeutic Innovation and Regulatory Science Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | SPRINGER HEIDELBERG |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1966 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Therapeutic Innovation and Regulatory Science ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Therapeutic Innovation and Regulatory Science
Psychotropic Drug Scheduling and Benzodiazepine Receptor Agonist Prescribing in Japan: An Interrupted Time Series Analysis.
- 8 Aug 2026
- Therapeutic innovation & regulatory science
Clinical and Economic Burden of Diseases with Accelerated Approval Therapies: Evidence of Unmet Patient Need.
- 8 Aug 2026
- Therapeutic innovation & regulatory science
The Changing Landscape of Global Biopharmaceutical Leadership, 2004-2024.
- 7 Aug 2026
- Therapeutic innovation & regulatory science
Correction to: BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations.
- 1 Aug 2026
- Therapeutic innovation & regulatory science
Integral Drug-Device Combinations and Medical Device Regulation Article 117: The European Medicines Agency Perspective.
- 1 Aug 2026
- Therapeutic innovation & regulatory science
Key Real-World Data Management Practices for Registry Evaluation and Quality Assurance.
- 1 Aug 2026
- Therapeutic innovation & regulatory science
Psychotropic Drug Scheduling and Benzodiazepine Receptor Agonist Prescribing in Japan: An Interrupted Time Series Analysis.
- 8 Aug 2026
- Therapeutic innovation & regulatory science
Clinical and Economic Burden of Diseases with Accelerated Approval Therapies: Evidence of Unmet Patient Need.
- 8 Aug 2026
- Therapeutic innovation & regulatory science
The Changing Landscape of Global Biopharmaceutical Leadership, 2004-2024.
- 7 Aug 2026
- Therapeutic innovation & regulatory science
Correction to: BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations.
- 1 Aug 2026
- Therapeutic innovation & regulatory science
Integral Drug-Device Combinations and Medical Device Regulation Article 117: The European Medicines Agency Perspective.
- 1 Aug 2026
- Therapeutic innovation & regulatory science
Key Real-World Data Management Practices for Registry Evaluation and Quality Assurance.
- 1 Aug 2026
- Therapeutic innovation & regulatory science